Compare GLOO & BNTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GLOO | BNTC |
|---|---|---|
| Founded | 2013 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 417.2M | 411.4M |
| IPO Year | N/A | 2020 |
| Metric | GLOO | BNTC |
|---|---|---|
| Price | $7.86 | $14.02 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 3 |
| Target Price | $13.75 | ★ $27.67 |
| AVG Volume (30 Days) | 78.3K | ★ 94.6K |
| Earning Date | 04-14-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 80.94 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $95.80 | N/A |
| Revenue Next Year | $53.68 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.63 | $9.85 |
| 52 Week High | $9.91 | $17.15 |
| Indicator | GLOO | BNTC |
|---|---|---|
| Relative Strength Index (RSI) | 73.28 | 74.54 |
| Support Level | $5.07 | $12.79 |
| Resistance Level | N/A | $14.21 |
| Average True Range (ATR) | 0.67 | 0.77 |
| MACD | 0.31 | 0.37 |
| Stochastic Oscillator | 95.92 | 94.17 |
Gloo Holdings Inc is engaged in building a technology platform company. It has provided a breadth of products, services, and solutions to the two primary stakeholders at the core of the faith and flourishing ecosystem: (1) network capability providers (NCPs) and (2) the churches and frontline organizations (CFLs) it serves. The company serves as a digital infrastructure between NCPs and CFLs. By facilitating efficient exchange between the two, Gloo enables both sides to succeed; CFLs gain access to resources and NCPs benefit from efficient distribution and targeted reach. This creates a virtuous cycle, strengthening the platform with each interaction. The Gloo platform includes a suite of technology, marketplace, and service solutions offered directly from Gloo or from Gloo's subsidiaries.
Benitec Biopharma Inc is a clinical-stage biotechnology company focused on the advancement of novel genetic medicines. Its technology has the potential to provide a one-shot cure for a wide range of diseases that are addressed by strict ongoing treatment regimens or that have no effective treatment or only palliative care options. The Company is developing a silence and replace-based therapeutic (BB-301) for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD), a chronic, life threatening genetic disorder.